VE800 is our rationally defined bacterial consortium candidate being developed for the treatment of patients with advanced or metastatic cancers. VE800 consists of 11 clonal human commensal bacteria strains manufactured under GMP conditions and selected for their ability to induce CD8+ T cells, potentiate the immune systems' attack of tumors and significantly amplify the effects of checkpoint inhibitors. The seminal work conducted by Vedanta and its scientific co-founder, Dr. Kenya Honda, underlying the discovery of VE800 was published in Nature (Tanoue et al. 2019).

Vedanta will be initiating a clinical study in patients with advanced and metastatic cancers in 2019 to evaluate VE800 in combination with the checkpoint inhibitor OPDIVO® (nivolumab) as part of its clinical collaboration agreement with its strategic investor Bristol-Myers Squibb.